Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)—protocol of randomised controlled trial AZIQUINE-ICU

Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)—protocol of randomised controlled trial AZIQUINE-ICU

Abstract Background Novel coronavirus SARS-CoV-2 is known to be susceptible in vitro to exposure to hydroxychloroquine and its effect has been found to be potentiated by azithromycin. We hypothesise that early administration of hydroxychloroquine alone or in combination with azithromycin can prevent...

Full description

Bibliographic Details
Main Authors: František Duška, Petr Waldauf, Milada Halačová, Václav Zvoníček, Jakub Bala, Martin Balík, Jan Beneš, Olga Klementová, Irena Kozáková, Viktor Kubricht, Anne Le Roy, Tomáš Vymazal, Veronika Řehořová, Vladimír Černý, on behalf of Czech Anaesthesia Clinical Trials and Audit Network
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Trials
Subjects:
Novel coronavirus
COVID-19
SARS-CoV-2
Azithromycin
Hydroxychloroquine
Respiratory failure
Online Access:http://link.springer.com/article/10.1186/s13063-020-04566-x

Internet

http://link.springer.com/article/10.1186/s13063-020-04566-x

Similar Items